Owner Topigen Pharmaceuticals Inc.

Inventors D'Anjou, Helene; Ferrari, Nicolay; Paquet, Luc

Agent Davies Collison Cave

Pub. Number AU-A-2009246000

PCT Pub. Number WO2009/137912

Priority 61/053,327 15.05.08 US

Filing date 31 March 2009

Wipo publication date 19 November 2009

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61K 31/7105 (2006.01) - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

A61K 31/712 (2006.01) - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

C07H 21/00 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C07H 21/02 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids